Evidence map›Paper›PMID 41981599›Full record

ArticleVirology journal2026

Molecular and antigenic characteristics of the influenza B virus in Guangzhou, 2022-2023.

Yang Liu, Shengzhen Wu, Yong Liu, Jingbin Chen, Juncong Xiao, Jiawei Zhang, Qingsheng Huang, Weiqi Pan, Dongni Lin, Yang Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yang Liu *State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510180, People's Republic of China.
Shengzhen Wu *KingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, 511436, China, People's Republic.
Yong Liu *KingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, 511436, China, People's Republic.
Jingbin ChenEngineering Technology Research Center of Intelligent Diagnosis for Infectious Diseases in Guangdong Province, Guangzhou, 511436, People's Republic of China.
Juncong XiaoKingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, 511436, China, People's Republic.
Jiawei ZhangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510180, People's Republic of China.
Qingsheng HuangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510180, People's Republic of China.
Weiqi PanState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510180, People's Republic of China.
Dongni LinKingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, 511436, China, People's Republic.
Yang WangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510180, People's Republic of China. wang_yang@gzlab.ac.cn.
Hon ChitinRespiratory Disease AI Laboratory On Epidemic Intelligence and Medical Big Data Instrument Applications, Faculty of Innovative Engineering, Macau University of Science and Technology, Macau SAR, People's Republic of China. cthon@must.edu.mo.
Zifeng YangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510180, People's Republic of China. jeffyah@163.com.
Xiaoyan DengEngineering Technology Research Center of Intelligent Diagnosis for Infectious Diseases in Guangdong Province, Guangzhou, 511436, People's Republic of China. dxyzgy@163.com.

Funding

Guangdong basic and applied basic research foundation 2022A1515110737Major Project of Guangzhou National Laboratory GZNL2024A01004National Key Research and Development Program of China 2024YFE0214800Platform project of Engineering Technology Research (Development) Center of Ordinary Colleges and Universities in Guangdong Province 2024GCZX010Science and Technology Development Fund of Macau SAR 005/2022/ALCScience and Technology Program of Guangzhou 2024B03J1385Self-supporting Program of Guangzhou Laboratory SRPG22-007
6 · The paper itself

Abstract

backgroundThe Influenza B virus (IBV), which accounts for nearly a quarter of annual global influenza-associated morbidity, represents a major human respiratory pathogen. Since late 2019, IBV transmission patterns have shifted markedly following the emergence of COVID-19, yet systematic studies on IBV prevalence before and after the pandemic remain limited.

methodsWe conducted systematic surveillance of 66 IBV isolates collected from Guangzhou during 2022-2023. Phylogenetic analysis of HA/NA genes was complemented with evolutionary rate estimation, hemagglutination inhibition assays, antigenic cartography, and structural modeling of hemagglutinin variants.

resultsWe revealed the distinct epidemic trends of IBVs in Southern China: clade V1A.3a.1/V1A.3a.2 co-circulated in 2022-2023 influenza season, while complete replacement of V1A.3a.1 by V1A.3a.2 in 2023-2024 season, which was driven by a 1.36-fold increase in the evolutionary rate of the HA gene (1.632 × 10

conclusionThis study elucidates the unique evolutionary and epidemic patterns of IBV in the subtropical region of southern China after the relaxation of COVID-19 NPIs, deciphers the molecular mechanism of clade replacement and antigenic diversification of the Victoria lineage V1A.3a subclade, and validates the sustained effectiveness of the WHO 2022 influenza B vaccine strain update in southern China. Our findings fill the gap in systematic surveillance of IBV in subtropical sentinel regions, identify Guangzhou as a key monitoring site for IBV evolutionary dynamics, and provide critical molecular and antigenic evidence for the optimization of regional influenza surveillance systems and vaccine strain selection strategies.

Indexed as

Antigens, ViralInfluenza B virusInfluenza, HumanAntigenic VariationChinaEvolution, MolecularHemagglutination Inhibition TestsHemagglutinin Glycoproteins, Influenza VirusHumansPhylogenyPhylogeographyAntigens, ViralHemagglutinin Glycoproteins, Influenza Virusantigenic characterizationInfluenza B virusMolecular epidemiology

Identifiers

PMID41981599
PMCPMC13214168

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.